key: cord-0787341-mfrpp9vh authors: Carugno, A.; Sena, P.; Raponi, F.; Robustelli Test, E.; Vezzoli, P. title: Bullous skin disease patients in a high‐epidemic COVID‐19 area, Bergamo, Italy date: 2020-06-01 journal: Br J Dermatol DOI: 10.1111/bjd.19266 sha: f1c61d7bc8bca692b1eba43920169cf8f6363bfe doc_id: 787341 cord_uid: mfrpp9vh Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are blistering disorders associated with barrier disruption, immune dysregulation and use of immunosuppressing systemic therapy. Patients with BP and PV have higher potential risk factors for infections secondary to skin alterations, comorbidity and chronic treatment with immunosuppressing agents. We decided to advise patients affected by bullous diseases to comply with hygiene rules, use of protective devices, encouraged observing social distancing measures and discouraged spontaneous suspensions of ongoing therapy, as well as informing the dermatologist in case of onset of symptoms, as suggested by the Italian Society of Dermatologists (SIDeMaST) 4 and several papers. [5] [6] [7] We report below our experience in Bergamo, an area of high epidemic for COVID-19. Our BP and PV patients are residents in the provinces of Bergamo (n=52 BP, n=26 PV, 83.9%), Milan (n=6 BP, n=0 PV, 6.5%), Brescia (n=2 BP, n=2 PV, 4.3%), Lecco (n=1 BP, n=1 PV, 2.2%), Cremona (n=1 BP, n=1 PV, 2.2%), Sondrio (n=0 BP, n=1 PV, 1.1%), Lombardy areas with a high incidence of COVID-19. 8 All patients (BP: n=62, 34 males, 28 females, mean age 78.6±10.1 years, range 52-98; PV: n=31, 17 males, 14 females, mean age 62.5±16.4 years, range 19-95)[ Table 1 ] were contacted by telephone 45-50 days after the beginning of the COVID-19 spread in the Bergamo area. Ten BP patients (16,1%) experienced suspected COVID-19 symptoms. Seven of these, reported coming into contact with patients with suspected (n=3) or known (n=4, positive nasal swab) COVID-19. Six BP patients (9.7%) experienced "mild/moderate" symptoms (e.g. flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved without hospitalization), four BP patients (6.5%) experienced "severe" symptoms (e.g. Pneumonia with respiratory failure) that needed hospitalization (all hospitalized patients received Hydroxychloroquine). All hospitalized patients had a positive COVID-19 nasal swab; three of these patients died (4.8%, mean age 85.0 years, all dead patients were suffering from severe cognitive impairment. Mean age of COVID-19 patients who died in our region was 79.0). 8 In March 2020 in Italy, nasal swabs were only made in hospitalized patients; serological tests are currently still limited to regional regulations. Seven PV patients (22,6%) experienced COVID-19 suspected symptoms. Four of these reported contact with suspected (n=3) or known (n=1) COVID-19 patients. Six PV patients (19.4%) experienced "mild/moderate" symptoms (as described above), one PV patient (3.2%) experienced "severe" symptoms that needed hospitalization. This patient (69 years old, comorbidity: previous breast cancer), confirmed with a positive COVID-19 nasal swab, has now recovered. For all those taking systemic steroid therapy, the current dosage was not considered immunosuppressive (>20mg/day). 5 No patient independently discontinued the current therapy for fear of recurrence of bullous lesions. Ongoing steroid or immunosuppressive therapy has been stopped for hospitalized patients. All pemphigoid and pemphigus patients were in remission, even This article is protected by copyright. All rights reserved ten newly diagnosed patients (<6 months). One pemphigus patient was treated with Rituximab 6 months earlier; he reports no COVID-19 symptoms. Observation of these data shows that the main risk factor of developing suspected COVID-19 symptoms was contact between the patient and a known/suspected COVID-19 individual. Furthermore, we have seen that longer disease duration is more frequently associated with suspected COVID-19 symptomatic patients. A longer duration of therapy, although not at immunosuppressive dosages, probably creates a condition of infectious risk predisposition. Contact with COVID-19 is probably the most important factor: in PB patients we found a statistical significance; in PV patients we found no significance, but we found a consistent trend. It must be considered that, given that many tests were performed, it's possible that some lower pvalues arose by chance. Observations on a larger number of patients will be required to evaluate whether these are confirmed trends. It is therefore important to create a communication channel with these patients to give clinical and human support and help in managing therapies. We found essential to advise and empower patients on activities that limit the risk of infection (hand hygiene, social distancing, use of protective devices), especially the most fragile, elderly and comorbid patients. Critical care utilization for the COVID-19 outbreak in Italy: early experience and forecast during an emergency response Papa Giovanni XXIII Bergamo Hospital at the time of the COVID-19 outbreak: letter from the warfront Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample Vademecum per i pazienti affetti da malattie bollose e malattie auto Accepted Article This article is protected by copyright. All rights reserved immuni Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases COVID-19 and Immunomodulator/Immunosuppressant Use in Dermatology Managing Cutaneous Immune-Mediated Diseases During the COVID-19 n=24) p Mean age (years ± SD, range) 79.5 ± 11 Mean age of onset (years ± SD, range) 75.4 ± 10.1 (57-89) 75.7 ± 10 We wish to express our gratitude to Dr. Fabio Carugno and Dr. Alberto Ferrari for their precious help and advice. This article is protected by copyright. All Characteristics of patients with bullous pemphigoid and pemphigus vulgaris. SD: standard deviation. 1 prednisone or equivalent.Means and standard deviations were compared between patients using a t-test for independent samples. Categorical variables were summarized as number and percentages of all patients and evaluated using chi-squared test or Fisher's exact test. Significance value was set at p < 0.05.